Home・Stock List・Danaher Corp

Danaher Corp

Closed

SectorHealthcare

194.61 -1.46

Buy Sell

Overview

Share price change

24h

Current

Min

192.43

Max

199.67

Key metrics
By Trading Economics
Income	-159M 870M
Sales	314M 6.3B
P/E Sector Avg	35.027 64.641
EPS	1.94
Dividend yield	0.75
Profit margin	13.887
Employees	58,000
EBITDA	-364M 1.1B

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+11.28% upside

Dividends
By Acuity
Dividend yield Sector Avg	0.75% 2.31%
Next Earnings	20 Oct 2026
Next Dividend date	30 Oct 2026
Next Ex Dividend date	25 Sept 2026

Market Stats
By TradingEconomics
Market Cap	-4.2B 138B
Previous open	196.07
Previous close	194.61

News Sentiment

By Acuity

50%

151 / 340 Healthcare

Danaher Corp Chart

Past performance is not a reliable indicator of future results.

Related News

3 Aug 2026, 22:51 UTC

News

Danaher Corp appointed Julie Sawyer Montgomery as President and CEO, effective October 1, 2026. Shares are trading higher in after-market hours.

31 Jul 2026, 23:01 UTC

Danaher Corp shares are lower in after-market trading, with no specific news identified to explain the decline amid broader market weakness.

30 Jul 2026, 18:01 UTC

Danaher Corp. shares are lower today, fluctuating within their one-month range amid volatility influenced by the Federal Reserve's interest rate decisions.

29 Jul 2026, 23:01 UTC

Danaher Corp shares are higher in after-market trading, reflecting a slight increase since Wednesday's close. The stock reached a recent high shortly after 5:10 PM ET.

28 Jul 2026, 23:01 UTC

Danaher Corp shares declined in after-hours trading amid broader market losses linked to concerns over artificial intelligence spending and competition from Chinese chipmakers.

27 Jul 2026, 23:16 UTC

Danaher Corp shares are lower in after-market trading, declining slightly since Monday's close. No specific company news has been identified to explain the movement.

24 Jul 2026, 20:06 UTC

News

Danaher Corp shares are lower amid concerns over reduced sales growth in its biotechnology segment, despite raising full-year earnings guidance to $8.45-$8.60.

23 Jul 2026, 10:01 UTC

Danaher Corp shares are lower in pre-market trading, continuing a decline since Wednesday's close and remaining below the 20-day moving average.

22 Jul 2026, 22:01 UTC

Danaher Corp shares are trading lower in after-market hours, continuing a trend of six consecutive sessions finishing lower amid rising crude oil prices and market volatility.

21 Jul 2026, 19:41 UTC

News

Social Media

Danaher Corp shares are lower after the company issued a cautious fiscal 2026 revenue growth forecast despite reporting better-than-expected second-quarter earnings and revenues.

20 Jul 2026, 23:41 UTC

Danaher Corp shares declined in after-market trading, continuing a trend of lower finishes amid concerns over economic momentum and a drop in the leading economic index.

Peer Comparison

Price change

Danaher Corp Forecast

Price Target

By TipRanks

11.28% upside

12 Months Forecast

Average 219.78 USD 11.28%

High 240 USD

Low 195 USD

Based on 20 Wall Street analysts offering 12 month price targets forDanaher Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

20 ratings

Buy

Hold

Sell

Based on 20 analysts giving stock ratings to Danaher Corp - Dist in the past 3 months.

Sentiment

By Acuity

151 / 340 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.